Latigo Biotherapeutics, Inc.
LTGO
IPO
$22.80
-$0.93-3.92%
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 4.58M | 5.80M | 2.82M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 25.81M | 23.44M | 25.75M | ||
| Operating Income | -25.81M | -23.44M | -25.75M | ||
| Income Before Tax | -25.80M | -22.96M | -25.84M | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -25.80M | -22.96M | -25.84M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -25.80M | -22.96M | -25.84M | ||
| EBIT | -25.81M | -23.44M | -25.75M | ||
| EBITDA | -25.76M | -23.39M | -25.68M | ||
| EPS Basic | -27.59 | -25.26 | -36.52 | ||
| Normalized Basic EPS | -17.24 | -15.79 | -22.82 | ||
| EPS Diluted | -27.59 | -25.26 | -36.52 | ||
| Normalized Diluted EPS | -17.24 | -15.79 | -22.82 | ||
| Average Basic Shares Outstanding | 935.00K | 908.90K | 707.50K | ||
| Average Diluted Shares Outstanding | 935.00K | 908.90K | 707.50K | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||